Exosome Component 9 Antibody (1090209) [Alexa Fluor™ Plus 488]

• Reactivity: Hu
• Clone: 1090209
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 488

Exosome Component 9 Antibody (1090209) [Alexa Fluor™ Plus 488] Summary

• Specificity: Detects a synthetic peptide specific for hEXOSC9 around amino acid 300 in Direct ELISA.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Exosome Component 9 Antibody (1090209) [Alexa Fluor™ Plus 488]

• Autoantigen PM/Scl 1
• EC 3.1.13
• exosome complex component RRP45
• exosome complex exonuclease RRP45
• Exosome Component 9
• p5
• p6
• P75 polymyositis-scleroderma overlap syndrome associated autoantigen
• PCH1D
• PM/Scl-75
• PMSCL autoantigen, 75kD
• PMSCL1
• polymyositis/scleroderma autoantigen 1 (75kD)
• Polymyositis/scleroderma autoantigen 1
• polymyositis/scleroderma autoantigen 1, 75kDa
• RRP45
• Rrp45p

Background

Exosome Component 9 (EXOSC9) is a 49 kDa protein and one of the six core proteins of the RNA exosome complex. It is known that EXOSC9 is necessary for the normal differentiation of epidermal tissues. EXOSC9 is also necessary for P-body formation, stress resistance and tumorigenicity in cancers. Depletion of EXOSC9 attenuates stress resistance and P-body formation in cancer cells and higher EXOSC9 activity correlates with poor prognosis in some types of cancers.

1. Yoshino S, Matsui Y, Fukui Y, Seki M, Yamaguchi K, Kanamori A, Saitoh Y, Shimamura T, Suzuki Y, Furukawa Y, Kaneko S, Seiki M, Murakami Y, Inoue JI, Sakamoto T. EXOSC9 depletion attenuates P-body formation, stress resistance, and tumorigenicity of cancer cells. Sci Rep. 2020 Jun 9;10(1):9275. doi: 10.1038/s41598-020-66455-2. PMID: 32518284; PMCID: PMC7283315. 
2. Quttina M, Waiters KD, Khan AF, Karami S, Peidl AS, Babajide MF, Pennington J, Merchant FA, Bawa-Khalfe T. Exosc9 Initiates SUMO-Dependent lncRNA TERRA Degradation to Impact Telomeric Integrity in Endocrine Therapy Insensitive Hormone Receptor-Positive Breast Cancer. Cells. 2023 Oct 20;12(20):2495. doi: 10.3390/cells12202495. PMID: 37887339; PMCID: PMC10605189.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.